trial

Transcranial Magnetic Stimulation (TMS) for Patients With Treatment Resistant Auditory Verbal Hallucination

NCTId NCT03762746
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 3 · Unknown
Enrollment 40 (estimated)
Sponsored by Dr Cipto Mangunkusumo General Hospital
Primary completion 2018-12-01
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 3
Status
Unknown
Enrollment
40 (estimated)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Triple
Start
2018-02-01
Primary completion
2018-12-01
Eligibility
ALL · 18 Years · 59 Years

Interventions & indications

Drugs
Transcranial Magnetic Stimulation

Sponsors

Dr Cipto Mangunkusumo General HospitalLead Sponsor

Investigators

1
Khamelia Malik, MDPrincipal Investigator

Sites

1 total
Jakarta Pusat, Indonesia

Linked catalysts

1
Transcranial Magnetic Stimulation (TMS) for Patients With Treatment Resistant Au — primary completion2018-12-01

Facts & assertions

4 sourced
Enrollment
40
Phase
PHASE3
Primary Completion Date
2018-12-01
Status
UNKNOWN
relationships
The graph out of here
drug
Transcranial Magnetic Stimulation
drug
lead_sponsor
Dr Cipto Mangunkusumo General Hospital
company
indication
Hallucinations, Verbal Auditory
indication
Hallucinations
indication
investigator
Khamelia Malik, MD
person